Boardroom Alpha
Boardroom Alpha
TELA · Additional Proxy Materials (DEFA14A) · Filed April 30, 2026

Tela Bio Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 30, 2026
Ticker
TELA
Accession
0001104659-26-053141
Boardroom Alpha · Filing insights

TELA Bio's board urges FOR all nominees and FOR Proposals 2-5, including increasing authorized equity-plan shares.

About Tela Bio Inc
Market cap
$31M
1Y TSR
−57.8%
3Y TSR
−57.1%
Board grade
C
Sector
Healthcare
CEO
Heather C Getz
Last annual meeting: Jun 9, 2026 · View full Tela Bio Inc profile →

 

 

 

United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

xFiled by the Registrant
¨Filed by a party other than the Registrant

 

Check the appropriate box:

¨Preliminary Proxy Statement
¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨Definitive Proxy Statement
xDefinitive Additional Materials
¨Soliciting Material under §240.14a-12

 

 

TELA BIO, INC.

 
 
(Name of Registrant as Specified In Its Charter)
 
 
 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

xNo fee required
¨Fee paid previously with preliminary materials
¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

GRAPHIC

Step 1: Go to www.envisionreports.com/TELA. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/TELA Online Go to www.envisionreports.com/TELA or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice 048Q8E Important Notice Regarding the Availability of Proxy Materials for the TELA Bio, Inc. Stockholder Meeting to be Held on June 9, 2026 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 Annual Report and Proxy Statement are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 29, 2026 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

GRAPHIC

Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/TELA. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to investorvote@computershare.com with “Proxy Materials TELA Bio” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 29, 2026. TELA Bio, Inc., Annual Meeting of Stockholders will be held virtually at https://event.accessnewswire.com/tela-2026 on June 9, 2026 at 10:00 a.m. E.S.T. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2, 3, 4 and 5: 1. Election of Directors: 01 - Joseph Capper 02 - Betty Jo Rocchio 03 - William Plovanic 2. To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026. 3. To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. 4. To approve an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan, as amended, to increase the authorized shares issuable thereunder by 3,500,000 shares. 5. To approve an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 4. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 Annual Report and Proxy Statement are available to stockholders at www.envisionreports.com/TELA PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Stockholder Meeting Notice

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Tela Bio Inc (TELA)

Reference

Frequently asked questions

When did Tela Bio Inc file this DEFA14A?
Tela Bio Inc (TELA) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 30, 2026. The accession number assigned by EDGAR is 0001104659-26-053141.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
TELA Bio's board urges FOR all nominees and FOR Proposals 2-5, including increasing authorized equity-plan shares. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Tela Bio Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Tela Bio Inc has filed under CIK 1561921, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer